Suppression of late asthmatic response by low-dose oral administration of interferon-β in the guinea pig model of asthma

Journal of Interferon and Cytokine Research

Volumn 19, Issue 8, 1999, Pages 887-894

  Satoh, Y U Ichiro ^a   Kasama, Kyoko ^b   Kuwabara, Mikiko ^b   Yimin, ^a   Diao, Hong Yan ^a   Nakajima, Hirofumi ^a   Kohanawa, Masashi ^a   Minagawa, Tomonori ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b TORAY INDUSTRIES INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; BETA INTERFERON; INTERFERON;

ANIMAL MODEL; ARTICLE; ASTHMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME INDUCTION; EOSINOPHIL; EXPERIMENTAL MODEL; GUINEA PIG; IMMUNOMODULATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

2',5'-OLIGOADENYLATE SYNTHETASE; ADMINISTRATION, ORAL; ANIMALS; ASTHMA; CELL COUNT; ENZYME INDUCTION; EOSINOPHILS; GUINEA PIGS; HUMANS; IMMUNOSUPPRESSION; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MALE;

ANIMALIA; CAVIA PORCELLUS; SUS SCROFA;

EID: 0032839875     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/107999099313415     Document Type: Article

References (34)

1. YONG, V.W., CHABOT, S., STUVE, O., and WILLIAMS, G. (1998). Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 51, 682-689.
2. PUNG, Y.H., VETRO, S.W., and BELLANTI, J.A. (1993). Use of interferons in atopic (IgE-mediated) diseases, Ann. Allergy 71, 234-238.
3. BELARDELLI, F. (1995). Role of interferons and other cytokines in the regulation of the immune response. Apmis 103, 161-179.
4. + T cell recruitment into tissue. J Immunol. 153, 1264-1270.
5. MAEDA, Y., MUSOH, K., SHICHIJO, M., TANAKA, H., and NAGAI, H. (1997). Interferon-beta prevents antigen-induced bronchial inflammation and airway hyperreactivity in mice. Pharmacology 55, 32-23.
6. HUTCHINSON, V., and CUMMINS, J.M. (1987). Low-dose oral interferon in patient with AIDS [letter]. Lancet 2, 1530-1531.
7. CABAN, J., MOSSOR-OSTROWSKA, J., ZYRKOWSKA- BIEDA. T., ZEJC, M., JANAS-SKULINA, U., CIESLA, A., CUMMINS, J.M., and GEORGIADES, J.A, (1993). Treatment of chronic viral hepatitis type B with oral mucosal administration of natural human interferon alpha lozenges. Arch. Immunol. Then Exp. 41, 229-235.
8. ZIELINSKA, W., PASZKIEWICZ, J., KORCZAK, A., WLASIUK, M., ZOLTOWSKA, A., SZUTOWICZ, A., CUMMINS, J.M., and GEORGIADES, J.A. (1993). Treatment of six patients with chronic active HCV hepatitis, with low dose natural human interferon alpha administered orally. Arch. Immunol. Ther. Exp. 41, 253-257.
9. LECCIONES, J.A., ABEJAR, N.H., DIMAANO, E.E., BARTOLOME, R., CINCO, S., MARIANO, N., YERRO, M.E., COBAR, S., and FUGGAN, B. (1998). A pilot double-blind, randomized, and placebo-controlled study of orally administered IFN-alpha-n1 (Ins) in pediatric patients with measles. J. Interferon Cytokine Res. 18, 647-652.
10. BROD, S.A., KERMAN, R.H., NELSON, L.D., MARSHALL, G.D., JR., HENNINGER, E.M., KHAN, M., JIN, R., and WOLINSKY, J.S. (1997). Ingested IFN-alpha has biological effects in humans with relapsing-remitting multiple sclerosis. Multiple Sclerosis 3, 1-7.
11. BROD, S.A., and KHAN, M. (1996). Oral administration of IFN-alpha is superior to subcutaneous administration of IFN-alpha in the suppression of chronic relapsing experimental autoimmune encephalomyelitis. J. Autoimmun. 9, 11-20.
12. BROD, S.A., SCOTT, M., BURNS, D.K., and PHILLIPS, J.T. (1995), Modification of acute experimental autoimmune encephalomyelitis in the Lewis rat by oral administration of type 1 interferons. J. Interferon Cytokine Res. 15, 115-122.
13. YOSHINO, S. (1996). Effects of oral administration of type I interferon on adjuvant arthritis in rats. Comp. Immunol. Microbiol. Infect. Dis. 19, 133-138.
14. STANTON, G.J., LLOYD, R.E., SARZOTTI, M., and BLALOCK, J.E. (1989). Protection of mice from Semliki Forest virus infection by lymphocytes treated with low levels of interferon. Mol. Biother. 1, 305-310.
15. NAGAO Y., YAMASHIRO, K., HARA, N., HORISAWA, Y., KATO, K., and UEMURA, A. (1998). Oral-mucosal administration of IFN-alpha potentiates immune response in mice. J. Interferon Cytokine Res. 18, 661-666.
16. TERASHI, Y., YUKAWA, T., FUKUDA, T., and MAKINO, S. (1988). Late phase response in the guinea pig airway caliber following inhaled antigen exposure. I. Comparative study of passively and actively sensitized models. Arerugi 37, 980-991.
17. ARIMA, M., YUKAWA, T., TERASHI, Y., and MAKING, S. (1994), Effect of inhaled cyclosporin A on the allergen-induced late asthmatic response and increased in airway hyperresponsiveness in a guinea pig model of asthma. Arerugi 43, 1316-1325.
18. ARIMA, M., YUKAWA, T., TERASHI, Y., SAGARA, H., and MARINO, S. (1991). Involvement of platelet activating factor (PAF) in ovalbumin antigen- induced late asthmatic response and increase of airway hyperresponsiveness in a guinea pig experimental model of asthma. Arerugi 40, 141-146.
19. YAMAZAKI, S., KURAMOTO, K., MATSUO, E., HOSOI, K., HARA, M., and SHIMIZU, H. (1989). Highly sensitive enzyme immunoassay of human interferon-beta 1. J. Immunoassay 10, 57-73.
20. OVERALL, J.C., JR., YEH, T.J., and KERN, E.R. (1984). Activity of human recombinant and lymphoblastoid interferons in human and heterologous cell lines. J Interferon Res. 4, 529-533.
21. CHRISTOFINIS, G.J. (1980). Heterospecific antiviral activity of human interferon on guinea pig endothelial cells. Dev. Biol. Stand. 46, 193-196.
22. SANTING, R.E., OLYMULDER, C.G., ZAAGSMA, J., and MEURS, H. (1994). Relationships among allergen-induced early and late phase airway obstructions, bronchial hyperreactivity, and inflammation in conscious, unrestrained guinea pigs. J. Allergy Clin. Immunol. 93, 1021-1030.
23. KALINER, M. (1989). Asthma and mast cell activation. J. Allergy Clin. Immunol. 83, 510-520.
24. NIELSEN, B.W., REIMERT, C.M., HAMMER, R., SCHIOTZ, P.O., and THESTRUP-PEDERSEN, K. (1994). Interferon therapy for atopic dermatitis reduces basophil histamine release, but does not reduce serum IgE or eosinophilic proteins. Allergy 49, 120-128.
25. REINHOLD, U., KUKEL, S., BRZOSKA, J., and KREYSEL, H.W. (1993). Systemic interferon gamma treatment in severe atopic dermatitis. J. Am. Acad. Dermatol. 29, 58-63.
26. JULLIEN, D., NICOLAS, J.F., FRAPAZ, A., and THIVOLET, J. (1993). Alpha interferon treatment in atopic dermatitis. Acta Derm. Venereol. 73, 130-132.
27. SWIETER, M., GHALI, W.A., RIMMER, C., and BEFUS, D. (1989). Interferon-alpha/beta inhibits IgE-dependent histamine release from rat mast cells. Immunology 66, 606-610.
28. PENE, J., ROUSSET, F., BRIERE, F., CHRETIEN, I., BONNEFOY, J.Y., SPITS, H., YOKOTA, T., ARAI, N., ARAI, K., BANCHEREAU, J., et al. (1988). IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons gamma and alpha and prostaglandin E2. Proc. Natl. Acad. Sci. USA 85, 6880-6884.
29. PUNNONEN, J., PUNNONEN, K., JANSEN, C.T., and KALIMO, K. (1993). Interferon (IFN)-alpha, IFN-gamma, interleukin (IL)-2, and arachidonic acid metabolites modulate IL-4-induced IgE synthesis similarly in healthy persons and in atopic dermatitis patients. Allergy 48, 189-195.
30. DE MONCHY, J.G., KAUFFMAN, H.F., VENGE, P., KOETER, G.H., JANSEN, H.M., SLUITER, H.J., and DE VRIES, K. (1985). Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. Am. Rev. Respir. Dis. 131, 373-376.
31. METZGER, W.J., ZAVALA, D., RICHERSON, H.B., MOSELEY, P., IWAMOTA, P., MONICK, M., SJOERDSMA, K., and HUNNINGHAKE, G.W. (1987). Local allergen challenge and bronchoalveolar lavage of allergic asthmatic lungs. Description of the model and local airway inflammation. Am. Rev. Respir. Dis. 135, 433-440.
32. NAKAJIMA, H., IWAMOTO, I., and YOSHIDA, S. (1993). Aerosolized recombinant interferon-gamma prevents antigen-induced eosinophil recruitment in mouse trachea. Am. Rev. Respir. Dis. 148, 1102-1104.
33. + T cells. J. Exp. Med. 177, 573-576.
34. KRISHNASWAMY, G., SMITH, J.K., SRIKANTH, S., CHI, D.S., KALBFLEISCH, J.H., and HUANG, S.K. (1996). Lymphoblastoid interferon-alpha inhibits T cell proliferation and expression of eosinophil-activating cytokines. J. Interferon Cytokine Res. 16, 819-827.